“WATCH & WAIT” ESPERAR Y VER EN EL CÁNCER DE RECTO
DOI:
https://doi.org/10.26754/ojs_arcol/archcolo.202136330Palabras clave:
watch & wait, respuesta clínica completa (cCR), preservación de órganoResumen
El objetivo de este trabajo ha sido realizar una revisión en la literatura sobre el enfoque de “watch & wait” o “esperar y ver” para los pacientes con cáncer de recto bajo y respuesta clínica completa (cCR) después del tratamiento con quimiorradioterapia (QRT) neodyuvante y así poder evitar la morbimortalidad asociada a la cirugía.
Los primeros en desarrollar esta idea fueron el grupo brasileño de Habr-Gama, quienes en el año 2004 publicaron un artículo con los resultados de un grupo seleccionado de pacientes tratados mediante dicho método. Concluyen que estos pacientes presentaban unos resultados a largo plazo similares a los de los pacientes tratados con cirugía. A partir de esta publicación numerosos grupos han realizado sus investigaciones al respecto.
Aunque los resultados obtenidos hasta la fecha son muy prometedores con tasas de supervivencia global y libres de enfermedad comparables a las obtenidas en pacientes operados que presentaron una respuesta patológica completa (pCR), no disponemos por el momento de ensayos clínicos aleatorizados que confirmen este nuevo esquema de tratamiento.
Descargas
Citas
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-tieulent J, Jemal A. Global Cancer Statistics, 2012. CA a cáncer J Clin. 2015; 65(2):87-108.
Ferlay J, Soerjomataram I, Ervik M, et al. Las Cifras Del Cáncer En España 2014.
Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2015. CA Cancer J Clin. 2015; 65(1):5-29.
Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy fro high-risk rectal cancer. N Engl J Med 1991; 324:709-715.
National Institutes of Health Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990; 264:1444-1450.
Sauer R, Becker H, Hohenberger W, et al. For the German Rectal Cancer. N Engl J Med 2004; 351:1731-40.
Gérard JP, Conroy T, Bonnetain F et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectalcancers: results of FFCD 9203.J Clin Oncol. 2006;24:4620-5.
Bosset JF1, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114-23.
Gaertner WB, Kwaan MR, Madoff RD, et al. Rectal cáncer: an evidence-based update for primary care providers. World Journal Gastroenterology 2015;21: 7659-71.
De Caluwé L, Van Nieuwenhove Y, Ceelen WP. Preoperative chemoradition versus radiation alone for stage II and III resectable rectal cáncer. Cochrane Database of Systematic Reviews 2013, Issue 2. Art. No: CD006041, DOI: 10.1002/14651858.CD006041.pub3.
Hofheinz RD, Wenz F, Post S, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol. 2012;13:579-88.
Allegra CJ, Yothers G, O'Connell MJ, et al. Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial.J Natl Cancer Inst. 2015;107.
Swedish Rectal Cancer Trial, Cedermark B, Dahlberg M, et al. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 1997; 336:980.
Birgisson H, Påhlman L, Gunnarsson U, et al. Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish Rectal Cancer Trial. J Clin Oncol 2005; 23:8697.
Sebag-Montefiore D, Stephens RJ, Steele R, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 2009; 373:811.
Quirke P, Steele R,Monson J, et al. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet 2009; 373:821.
Kapiteijn E, Marijnen CA, NagtegaalI D, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001; 345:638.
Peeters KC, Marijnen CA, NagtegaalI D,et al.The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 2007; 246:693.
Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006; 93:1215.
Ngan SY, Burmeister B,Fisher RJ, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol 2012; 30:3827.
M.J. Graney, C.M. Graney. Colorectal surgery from antiguity to the modern era. Dis Colon Rectum, 23 (1980), pp. 432-441.
W.E. Miles. A method of performing abdominoperineal excision for carcinoma of the rectum and of the terminal portion of the pelvic colon. Lancet, 2 (1908), pp. 1812-1813.
L. Ruo, J.G. Guillem. Major 20th-century advancements in the management of rectal cancer. Dis Colon Rectum, 42 (1999), pp. 563-578.
G. Slaney. Results of treatment of carcinoma of the colon and rectum. Mod Trends Surg, 3 (1971), pp. 69-89.
R.J. Heald, R.D. Ryall. Recurrence survival after total mesorectal excision for rectal cancer. Lancet, 1 (1986), pp. 1479-1482.
M. Jacobs, J.C. Verdeja, H.S. Goldstein. Minimally invasive colon resection (laparoscopic colectomy). Surg Laparosc Endosc, 1 (1991), pp. 144-150.
R. Veldkamp, E. Kuhry, W.C. Hop, J. Jeekel, G. Kazemier, H.J. Bonjer, COlon cancer Laparoscopic or Open Resection Study Group (COLOR)., et al. Laparoscopic surgery versus open surgery for colon cancer: Short-term outcomes of a randomised trial. Lancet Oncol, 6 (2005), pp. 477-484.
M. Buunen, R. Veldkamp, W.C. Hop, E. Kuhry, J. Jeekel, E. Haglind, Colon Cancer Laparoscopic or Open Resection Study Group, et al. Survival after laparoscopic surgery versus open surgery for colon cancer: Long-term outcome of a randomised clinical trial. Lancet Oncol, 10 (2009), pp. 44-52.
P.J. Guillou, P. Quirke, H. Thorpe, J. Walker, D.G. Jayne, A.M. Smith, MRC CLASICC trial group, et al. Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): Multicentre, randomised controlled trial. Lancet, 365 (2005), pp. 1718-1726.
S.Y. Jeong, J.W. Park, B.H. Nam, S. Kim, S.B. Kang, S.B. Lim, et al. Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): Survival outcomes of an open-label, non inferiority, randomised controlled trial. Lancet Oncol, 15 (2014), pp. 767-774.
M.H. Van der Pas, E. Haglind, M.A. Cuesta, A. Fürst, A.M. Lacy, W.C. Hop, Colorectal cancer Laparoscopic or Open Resection II (COLOR II) Study Group, et al. Laparoscopic versus open surgery for rectal cancer (COLOR II): Short-term outcomes of a randomised, phase 3 trial. Lancet Oncol, 14 (2013), pp. 210-218.
H.J. Bonjer, C.L. Deijen, G.A. Abis, M.A. Cuesta, M.H. van der Pas, E.S. de Lange-de Klerk, COLOR II Study Group, et al. A randomized trial of laparoscopic versus open surgery for rectal cancer. N Engl J Med, 372 (2015), pp. 1324-1332.
Sylla P, Bordeianou LG, Berger D, et al. A pilot study of natural orifice transanal endoscopic total mesorectal excision with laparoscopic assistance for rectal cancer. Surgical endoscopy. 2013; 27:3396-405.
A. Pigazzi, J.D. Ellenhorn, G.H. Ballantyne, I.B. Paz Robotic-assisted laparoscopic low anterior resection with total mesorectal excision for rectal cancer. Surg Endosc., 20 (2006), pp. 1521-1525.
Schneider EB, Hyder O, Brooke BS, Efron J, Cameron JL, Edil BH, Schulick RD, Choti MA, Wolfgang CL, Pawlik TM. Patient readmission and mortality after colorectal surgery for colon cancer: impact of length of stay relative to other clinical factors. J Am Coll Surg 2012; 214: 390-398; discussion 398-399 [PMID: 22289517 DOI: 10.1016/j.jamcollsurg.2011.12.025].
Paun BC, Cassie S, MacLean AR, Dixon E, Buie WD. Postoperative complications following surgery for rectal cancer. Ann Surg 2010; 251: 807–18.
Lange MM, van de Velde CJ. Urinary and sexual dysfunction after rectal cancer treatment. Nat Rev Urol 2011; 8: 51-57.
Vonk Klaasen SM, de Vocht HM, den Ouden ME. Ostomy-related problems and their impact on quality of life of colorectal cancer ostomates: a systematic review. Qual Life Res 2016; 25: 125-133.
Borstlap WA, Coeymans TJ, Tanis PJ et al. Meta-analysis of oncological outcomes after local excision of pT1-2 rectal cancer requiring adjuvant chemoradiotherapy or completion surgery. Br J Surg 2016; 103: 105-1116.
Maas M, Nelemans PJ, Valentini V, Das P, Rödel C, Kuo LJ, Calvo FA, García-Aguilar J, Glynne-Jones R, Haustermans K, Mohiuddin M, Pucciarelli S, Small W, Suárez J, Theodoropoulos G, Biondo S, Beets-Tan RG, Beets GL. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 2010; 11: 835-844 [PMID: 20692872 DOI: 10.1016/ S1470-2045(10)70172-8].
Park IJ, You YN, Agarwal A, Skibber JM, Rodriguez-Bigas MA, Eng C, Feig BW, Das P, Krishnan S, Crane CH, Hu CY, Chang GJ. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol 2012; 30: 1770-1776 [PMID: 22493423 DOI: 10.1200/JCO.2011.39.7901]
Schrag D Weiser MR Goodman KAet al. Neoadjuvant FOLFOX-bev, without radiation, for locally advanced rectal cancer. J Clin Oncol. 2010;28(Suppl):15S.
Habr-Gama A. Assessment and management of the complete clinical response of rectal cancer to chemoradiotherapy. Colorectal Dis. 2006;8 Suppl 3:21–24. [PubMed] [Google Scholar]
Habr-Gama A, Gama Rodrigues J, Sao Juliao GP et al. Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impacto f salvage therapy on local disease control. Int J Radiat Oncol Biol Phys 2014; 88: 822-8.
Habr-Gama A, Oliva R, Nadalin W et al. Operative versus nonoperative treatment for stage 0 distal rectal cáncer following chemoradiation therapy. Ann Surg 2004; 240: 711-718.
Habr-gama, A., Perez, R. O., & Julião, G. P. S. Nonoperative Approaches to Rectal Cancer: A Critical Evaluation. Semin Radiat Oncol. 2011; 21(3): 21:234- 239.
Smith JJ, Chow OS, Gollub MJ et al. Rectal Cancer Consortium. BMC Cancer 2015. Doi: 10.1186/s12885-015-1632-z.
Dalton RS, Velineni R Osborne ME et al. A single center experience of chemoradiotherapy for rectal cancer: is there potential for non-operative Management? Colorectal Dis 2012; 14: 567-71.
Marcos E Pozo, Sandy H Fang. Watch and wait approach to rectal cancer: A review. World J Gastrointest Surg 2015 November 27; 7(11): 306-312.
On J, Aly EH. Watch and wait in rectal cancer: summary of the current evidence. Int J Colorectal Dis 2018; 33: 1159-1168.
van der Paardt MP, Zagers MB, Beets-Tan RGH, Stoker J, Bipat S (2013) Patients who undergo preoperative chemoradiotherapy for locally advanced rectal cancer restaged by using diagnostic MR imaging: a systematic review and meta-analysis. Radiology 269(1):101–112.
Patel UB, Blomqvist LK, Taylor F, George C, Guthrie A, Bees N, Brown G (2012) MRI after treatment of locally advanced rectal cancer: how to report tumor response—the MERCURY experience. Am J Roentgenol 199(4):W486–W495.
Francois Y, Nemoz CJ, Baulieux J, Vignal J, Grandjean J-P, Partensky C, Souquet JC, Adeleine P, Gerard JP (1999) Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol 17(8):2396–2396.
Petrelli F, Sgroi G, Sarti E, Barni S (2016) Increasing the interval between neoadjuvant chemoradiotherapy and surgery in rectal can- cer: a meta-analysis of published studies. Ann Surg 263(3):458–464.
Andrew G Renehan, Lee Malcomson, Richard Emsley, et al. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis. Lancet Oncol 2016; 17: 174–83.
Dossa F, Chesney TR, Acuna SA, Baxter NN (2017) A watch-and- wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a sys- tematic review and meta-analysis. Lancet Gastroenterol Hepatol 2(7):501–513
Dattani M, Heald RJ, Goussous G et al. Oncological and survival outcomes in watch and wait patients with a clinical complete response after neoadjuvant chemoradiotherapy for rectal cancer. A systematic review and pooled analysis. Ann Surg 2018; doi 10.1097/SLA.
Battersby NJ, How P, Moran B, et al. Prospective validation of a low rectal cancer magnetic resonance imaging staging system and development of a local recurrence risk stratification model: the MERCURY II study. Ann Surg. 2016;263:751 – 760.
Smith JJ, Strombom P, Chow OS, et al. Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy. JAMA Oncol 2019; 5:e18589
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2021 María del Carmen Álvarez Sánchez
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Creative Commons License 4.0.
Los autores son los depositarios del copyright Creative Commons
Archivos de Coloproctología está sujeta a una licencia de Reconocimiento 4.0 Internacional de Creative Commons [CC-BY]
